6801 N. Capital of Texas Highway
Suite 300 Building 1
Austin, TX 78731
United States
512 501 2444
https://www.cassavasciences.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 29
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Richard Jon Barry | Executive Chairman of the Board | 7.5k | N/A | 1959 |
Mr. Eric J. Schoen | Chief Financial Officer | 460k | N/A | 1968 |
Mr. R. Christopher Cook | Senior VP, Company Secretary & General Counsel | 425k | N/A | 1964 |
Mr. Remi Barbier | Executive Officer | 1.2M | 598.57k | 1960 |
Dr. James W. Kupiec M.D. | Chief Medical Officer | 435k | N/A | 1953 |
Dr. George Thornton Ph.D. | Senior Vice President of Technology | N/A | N/A | N/A |
Mr. Michael Zamloot | Senior Vice President of Technical Operations | N/A | N/A | N/A |
Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
Dr. Lindsay H. Burns Ph.D. | Senior Vice President of Neuroscience | N/A | N/A | N/A |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc.’s ISS governance QualityScore as of 28 August 2024 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 8; Compensation: 8.